Filing Details

Accession Number:
0001127602-20-026862
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-10-13 16:20:07
Reporting Period:
2020-09-15
Accepted Time:
2020-10-13 16:20:07
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1145197 Insulet Corp PODD Surgical & Medical Instruments & Apparatus (3841) 043523891
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1667779 P Michael Spears C/o Insulet Corporation
100 Nagog Park
Acton MA 01720
Svp, Ra And Compliance No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2020-09-15 2,500 $0.00 8,947 No 5 G Direct
Common Stock Acquisiton 2020-10-09 13,350 $29.87 22,297 No 4 M Direct
Common Stock Acquisiton 2020-10-09 8,907 $29.26 31,204 No 4 M Direct
Common Stock Disposition 2020-10-09 22,257 $246.10 8,947 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 5 G Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Disposition 2020-10-09 13,350 $0.00 13,350 $29.87
Common Stock Employee Stock Option (Right to Buy) Disposition 2020-10-09 8,907 $0.00 8,907 $29.26
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2025-07-27 No 4 M Direct
3,735 2026-02-24 No 4 M Direct
Footnotes
  1. The transactions reported in this Form 4 were effected pursuant to an existing Rule 10b5-1 trading plan.
  2. The price reported represents the weighted average sale price of the shares sold. The shares were sold at varying prices in the range of $244.63 to $251.38. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
  3. This option is subject to a four-year vesting period with 25% of the total award vesting one year after the grant date and the remainder vesting in equal quarterly installments each quarter thereafter for 12 quarters, subject to continued employment.